Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Phosphorus Metabolism Disorders

ClinicalTrials.gov lists 256 trials for Phosphorus Metabolism Disorders or a narrower condition beneath it. Kyowa Kirin Co., Ltd. has the most among industry and government lead sponsors, with 17.

MeSH D010760 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 17 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 33 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 65 Phase 4 Phase 4 26 Not applicable Not applicable 42 Observational Observational 62 Phase 1 Phase 1 17 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 33 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 65 Phase 4 Phase 4 26 Not applicable Not applicable 42 Observational Observational 62

Trials per phase (log scale)

1 more section with rows

5 of the 256 trials are tagged with Phosphorus Metabolism Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Phosphorus Metabolism Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Phosphorus Metabolism Disorders trials start? (24)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 21

2003: 2 trials (Observational 2) 2004: 2 trials (Observational 1, Phase 1 1) 2005: 7 trials (Observational 1, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1 1) 2006: 10 trials (Observational 1, Phase 3 4, Phase 2 2, Phase 1/2 2, Phase 1 1) 2007: 12 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2 2) 2008: 11 trials (Not applicable 3, Phase 3 1, Phase 2 4, Phase 1 3) 2009: 19 trials (Observational 4, Not applicable 5, Phase 3 6, Phase 2 3, Phase 1 1) 2010: 15 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 7, Phase 2 1, Phase 1 2) 2011: 10 trials (Observational 2, Not applicable 5, Phase 3 2, Phase 1/2 1) 2012: 11 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2013: 12 trials (Observational 2, Not applicable 1, Phase 3 6, Phase 2 2, Phase 1 1) 2014: 10 trials (Not applicable 1, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2015: 9 trials (Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 1, Phase 1/2 1) 2016: 9 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 1, Phase 1 1) 2017: 14 trials (Observational 2, Not applicable 2, Phase 4 4, Phase 3 5, Phase 1 1) 2018: 15 trials (Observational 7, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 1) 2019: 21 trials (Observational 6, Not applicable 3, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1 2) 2020: 13 trials (Observational 6, Not applicable 1, Phase 4 3, Phase 2 1, Phase 1/2 2) 2021: 14 trials (Observational 4, Phase 4 4, Phase 3 6) 2022: 6 trials (Observational 3, Not applicable 1, Phase 3 2) 2023: 11 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1) 2024: 8 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 2 1, Phase 1/2 1) 2025: 6 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 6
2025 6
2024 8
2023 11
2022 6
2021 14
2020 13
2019 21
2018 15
2017 14

Showing 10 of 24 earlier years.

Start your 14-day trial Email me all 24 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 187 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Phosphorus Metabolism Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 17
Phase 1/2 8
Phase 2 33
Phase 2/3 2
Phase 3 65
Phase 4 26
Not applicable 42
Observational 62
Expanded access 1

How many Phosphorus Metabolism Disorders trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 16
Active, not recruiting 6
Available 1
Completed 170

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Phosphorus Metabolism Disorders trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Kyowa Kirin Co., Ltd. 17
Bayer 11
Tanabe Pharma Corporation 10
Astellas Pharma Inc 8
Ardelyx 6

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Phosphorus Metabolism Disorders? (10)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Burosumab 20
Sevelamer Carbonate 18
Sevelamer 14
Tenapanor 13
PA21 11

Showing 5 of 10 drugs.

Start your 14-day trial Email me all 10 drugs as a PDF

Interventions as named in the registry (5)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule 17
Ferric Citrate 11
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet 3
Fermagate 3
Paricalitol 3

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Phosphorus Metabolism Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 70 18
Sepsis 58 13
Hypertension 36 11
Renal transplant 36 7
Cardiac failure congestive 35 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Phosphorus Metabolism Disorders? (7)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annual review of medicine 2010 Yes
Genetic disorders of renal phosphate transport. The New England journal of medicine 2010 Yes
Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Seminars in dialysis 2007 Yes
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney international 2004 Yes
Bisphosphonate-induced osteopetrosis. The New England journal of medicine 2003 Yes

Showing 5 of 7 publications.

Start your 14-day trial Email me all 7 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages